Growth Hormone Deficiency Market: Opportunity Analysis and Forecast to 2024
"The
Latest Research Report OpportunityAnalyzer: Growth Hormone Deficiency
- Opportunity Analysis and Forecast to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About Growth Hormone Deficiency
Market
GlobalData estimates the 2014
sales for growth hormone deficiency (GHD) at approximately $1.26
billion across the 7MM covered in this report. The market will grow
moderately at a CAGR of 4.08% during the 10-year forecast period,
generating sales of approximately $1.88 billion at the end of 2024.
The US market is expected to grow the fastest of the three regions,
recording a CAGR of 4.88% and generating around 59% of global sales
in 2024. The major driver for this growth across the 7MM will be the
launch of long-acting biobetter growth hormones (GH), which will
rapidly take away shares from the currently marketed daily injectable
growth hormones.
Highlights
Key Questions Answered
- Overall, the greatest unmet need
in the GHD space is the issue with treatment adherence and
compliance. There are other prominent unmet needs highlighted by the
Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs
fulfil these unmet needs of the market?
- The 10-year forecast period will
mark the launch of six pipeline long-acting GH drugs. How will the
sales of the existing drugs be impacted? Which of the pipeline drugs
will have the highest peak sales at the highest CAGR, and why?
- What are the roles of payers in
this highly competitive disease space? How does this affect market
shares of the GH brands, especially in the US? What are the chances
of reimbursement for the long-acting GH drugs in pipeline?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/443290
Key Findings
- The major driver for growth in
the GHD market during the forecast period will be the launch of six
long-acting GH biobetters with less frequent dosing regimens. These
will not only boost the use of GH, but will in addition increase
adherence and compliance in patients.
- KOLs interviewed by GlobalData
opined that these long-acting biobetters will eventually replace most
of the patient shares of currently marketed GH drugs during the
forecast period.
- In other interviews, US payers
revealed to GlobalData the current trend of GH manufacturers
negotiating with insurance companies as a means of gaining market
access for their particular brand.
- Low disease awareness and
stringent regulatory policies lead to sub-optimal dosing and
treatment outcomes in the Japanese market.
- Companies in the early-stage GHD
space demonstrate two major trends development of long-acting GH
formulations and innovation in GH delivery strategies.
Scope
- Overview of GHD, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized GHD therapeutics
market revenue, annual cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the GHD
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global GHD therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the GHD therapeutics
market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the GHD therapeutics market
in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM GHD
therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology
19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Symptoms 22
3.3 Diagnosis 22
3.4 Prognosis 23
3.5 Quality of Life 23
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/443290
4 Epidemiology 25
4.1 Disease Background 25
4.1.1 GHD in Children 25
4.1.2 GHD in Adults 26
4.2 Risk Factors and Comorbidities
26
4.3 Global Trends 28
4.3.1 GHD in Children 29
4.3.2 GHD in Adults 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 36
4.4.1.1 7MM 36
4.4.1.2 Diagnosed Cases of GHD in
Children 37
4.4.1.3 Diagnosed Cases of GHD in
Adults 38
4.4.1.4 GHD Etiological
Classification in Children 38
4.4.1.5 GHD Etiological
Classification in Adults 39
4.4.2 Sources Not Used 40
4.4.3 Forecast Assumptions and
Methods 41
4.4.3.1 Temporal Trends 41
4.4.3.2 Sex-Specific Trends 41
4.4.3.3 Diagnosed Prevalent Cases
of GHD in Children 41
4.4.3.4 Diagnosed Prevalent Cases
of GHD in Adults 42
4.4.3.5 GHD Etiological
Classification in Children 43
4.4.3.6 GHD Etiological
Classification in Adults 43
4.5 Epidemiological Forecast of
GHD (2014-2024) 44
4.5.1 Diagnosed Prevalent Cases of
GHD 44
4.5.2 Diagnosed Prevalent Cases of
GHD by Sex 46
4.5.3 Diagnosed Prevalent Cases of
GHD by Age 47
4.5.3.1 Diagnosed Prevalent Cases
of GHD in Children 47
4.5.3.2 Diagnosed Prevalent Cases
of GHD in Adults 49
4.5.4 Age-Adjusted Diagnosed
Prevalence of GHD 50
4.5.5 Diagnosed Prevalent Cases of
GHD in Children by Etiological Classification 51
4.5.6 Diagnosed Prevalent Cases of
GHD in Adults by Etiological Classification 52
4.6 Discussion 53
4.6.1 Epidemiological Forecast
Insight 53
4.6.2 Limitations of the Analysis
54
4.6.3 Strengths of the Analysis 55
5 Competitive Assessment 56
5.1 Overview 56
5.2 Treatment Algorithm 56
5.3 Market Access, Reimbursement,
and Clinical Practice 58
5.4 Product Profiles Recombinant
Human Growth Hormones 60
5.4.1 Overview 60
5.4.1.1 Genotropin 61
5.4.1.2 Humatrope 62
5.4.1.3 Norditropin 62
5.4.1.4 Nutropin AQ 63
5.4.1.5 Saizen 64
5.4.1.6
Tev-Tropin/Zomacton/Growject 64
5.4.1.7 Omnitrope Biosimilar 65
5.4.2 Efficacy 68
5.4.2.1 Pediatric GHD 68
5.4.2.2 Adult GHD 68
5.4.3 Safety 69
5.4.3.1 Pediatric GHD 69
5.4.3.2 Adult GHD 69
5.4.4 SWOT Analysis 70
6 Unmet Needs Assessment and
Opportunity Analysis 71
6.1 Overview 71
6.2 Improved Adherence and
Compliance 72
6.2.1 Unmet Needs 72
6.2.2 Gap Analysis 74
6.2.3 Opportunity 74
6.3 Early Diagnosis 75
6.3.1 Unmet Needs 75
6.3.2 Gap Analysis 75
6.3.3 Opportunity 76
6.4 Disease Awareness and
Regulatory Policy in Japan 76
6.4.1 Unmet Needs 76
6.4.2 Gap Analysis 77
6.4.3 Opportunity 77
6.5 Insurance Policies that Impact
Patient Access 78
6.5.1 Unmet Needs 78
6.5.2 Gap Analysis 79
6.5.3 Opportunity Analysis 79
6.6 Safer Treatments for Cancer
Survivors 79
6.6.1 Unmet needs 79
6.6.2 Gap Analysis 80
6.6.3 Opportunity Analysis 80
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment